REVIEW

A *lex naturalis* delineates components of a human-specific, adrenal androgen-dependent, p53-mediated 'kill switch' tumor suppression mechanism

Jonathan Wesley Nyce

ACGT Biotechnology, Collegeville, Pennsylvania, USA

Correspondence should be addressed to J W Nyce: professor@acgt.us

Abstract

We have recently described in this journal our detection of an anthropoid primate-specific, adrenal androgen-dependent, p53-mediated, 'kill switch' tumor suppression mechanism that reached its fullest expression only in humans, as a result of human-specific exposure to polycyclic aromatic hydrocarbons caused by the harnessing of fire – but which has components reaching all the way back to the origin of the primate lineage. We proposed that species-specific mechanisms of tumor suppression are a generalized requirement for vertebrate species to increase in body size or lifespan beyond those of species basal to their lineage or to exploit environmental niches which increase exposure to carcinogenic substances. Using empirical dynamic modeling, we have also reported our detection of a relationship between body size, lifespan, and species-specific mechanism of tumor suppression (and here add carcinogen exposure), such that a change in any one of these variables requires an equilibrating change in one or more of the others in order to maintain lifetime cancer risk at a value of about 4%, as observed in virtually all larger, longer-lived species under natural conditions. Here we show how this relationship, which we refer to as the *lex naturalis* of vertebrate speciation, elucidates the evolutionary steps underlying an adrenal androgen-dependent, human-specific 'kill switch' tumor suppression mechanism; and further, how it prescribes a solution to 'normalize' lifetime cancer risk in our species from its current aberrant 40% to the 4% that characterized primitive humans. We further argue that this prescription writ by the *lex naturalis* represents the only tenable strategy for meaningful suppression of the accelerating impact of cancer upon our species.

Key Words

- ▶ p53
- ▶ TP53
- ▶ DHEA
- ▶ cancer prevention
- ▶ vitamin C

Endocrine-Related Cancer
(2020) 27, R51–R65

Introduction

Consider these longstanding, unanswered questions in human biology. Why the extraordinary levels of circulating dehydroepiandrosterone sulfate (DHEAS) in humans – *ten thousand times higher than in mice and rats* – when its proximate metabolite (DHEA) is a potentially

irreversible inhibitor of so crucial an enzyme as glucose-6-phosphate dehydrogenase (G6PD), the major source of the NADPH required to detoxify reactive oxygen species (ROS)? Why is the evolution of adrenarche, exclusively in humans and only our closest primate relatives, designed

to flood the circulation with DHEAS just prior to the onset of adult body size? Why did humans lose the capacity to synthesize vitamin C, making our species vulnerable to the pernicious disease of scurvy? Why the evolution exclusive to our direct lineage of an alteration in the glucose-6-phosphatase (G6PC) promoter that enables inhibition of G6PD become irreversible in the presence of DHEA? And why the inactivation of uric acid oxidase (UOX) in our species, leading to the accumulation of extraordinary levels of circulating uric acid, precipitating the disease of gout? The uncovering of the *lex naturalis* provides a powerful answer to these longstanding, unanswered questions: Each is a component of a p53-mediated, adrenal androgen-dependent, species-specific 'kill switch' tumor suppression mechanism that fundamentally controls lifetime cancer risk in humans. If they had not occurred, our species could not have evolved.

Uncovering the *lex naturalis* revealed that malignant transformation represents a fundamental force opposing vertebrate speciation, and that species-specific mechanisms of tumor suppression evolved as countermeasures to suppress such opposition when speciation involved adaptive increases in body size and lifespan (Nyce 2018, 2019). Nowhere is this more apparent than in the 5000-fold increase in size from basal primates, which weighed on the order of 40 g (Gebo *et al.* 2017), to extant gorillas, which weigh as much as 200 kg. As we demonstrate here, each branchpoint in the evolution of primates that was followed by an increase in body size and lifespan was preceded by an improvement in the adrenal androgen-dependent kill switch tumor suppression mechanism.

Primates emerged as viable species by successfully responding to the environmental conditions imposed by the PETM

Strepsirrhine (lemurs, lorises, and galagos) and Haplorrhine (tarsiers and anthropoid) primates emerged together during the Paleocene–Eocene Thermal Maximum (PETM), a period in earth's history beginning about 56 million years ago that was characterized by a 5–8°C increase in global average temperatures. This global warming was generated by a worldwide incendiary landscape (Robson *et al.* 2014, Fung *et al.* 2018) apparently precipitated by an extraterrestrial impact (Schaller *et al.* 2016). Such a landscape would have substantially increased exposure to polycyclic aromatic hydrocarbons (PAHs), potent carcinogens formed by the incomplete

combustion of organic materials. The emergence of the major subdivisions of primates during the PETM and the recent observation that extant chimpanzees preferentially scavenge at fire-combusted sites (Pruetz & Herzog 2017) suggests that primates may have required a lineage-specific tumor suppression mechanism that helped them cope with, or even enabled them to exploit, a PAH-contaminated biosphere.

The 'kill switch' tumor suppression mechanism that we reported is based on the extraordinarily high levels of circulating DHEAS that distinguish the primate lineage (Supplementary Fig. 1, see section on [supplementary materials](#) given at the end of this article), the very highest of which levels occur in humans, the only primate species to harness fire as a tool. Inactivation of TP53 (the human p53 gene) triggers import of DHEAS from the circulation, whereupon it is de-sulfated intracellularly to DHEA, an uncompetitive inhibitor of G6PD. That DHEA is an uncompetitive inhibitor of so critical an enzyme as G6PD has gone unappreciated for a very long time. Uncompetitive inhibition is otherwise unknown in biological systems because, in the presence of large amounts of inhibitor and substrate, it rapidly becomes irreversible (Cornish-Bowden 1986). G6PD is the cell's major source of the NADPH required not only for reductive biosyntheses, but also to maintain redox systems in the reduced state necessary for them to neutralize reactive oxygen species (ROS) that are constantly generated in the cell. In the TP53-inactivated human cell, the levels of both DHEA inhibitor and glucose-6-phosphate (G6P) substrate rapidly rise, causing uncompetitive inhibition of G6PD to become irreversible, resulting in a catastrophic increase in ROS. Thus, the triggering of this kill switch by the inactivation of TP53 in human cells extinguishes potentially malignant cells at the single-cell stage, before they have the opportunity to evolve into the heterogeneous tumor cell populations that have made cancer incurable up to now.

If the kill switch is an effective tumor suppression system, why is lifetime cancer risk in modern humans a staggering 40%, ten times higher than has been reported for most other large, long-lived animals (Abegglen *et al.* 2015)? The human-specific tumor suppression system that evolved for the 25–30-year lifespan that has characterized humans for almost all of our existence as species (Supplementary Fig. 2). Thus, circulating DHEAS levels reach their peak at 25 years of age in humans and decline precipitously thereafter to levels inadequate to effectively trigger the kill switch. This was all that was necessary

for 99.95% of our species' existence. With lifespans that have now more than tripled, reducing DHEAS levels far below the threshold required for triggering the kill switch mechanism, modern humans are aging under the protection of only the canonical repertoire of the p53 tumor suppressor, so well-studied in the p53-knockout mouse, which by itself is effective only for vertebrate animals of small size and short lifespan – such as mice and proto primates, both of which have/had body masses of about 40 g. TP53 mutations in human tumors are thus fossils of kill switch failure, and the failure of our species-specific mechanism of tumor suppression is the cause of the 40% lifetime risk of cancer being experienced by modern humans. However, since the human-specific kill switch operates via a small molecule, DHEAS, it appears to be pharmacologically tractable. That is, it may be possible to 'normalize' lifetime cancer risk in our species from its current aberrant 40% to the 4% of most other large, long-lived species by pharmacologically reconstituting circulating DHEAS to peak levels and maintaining such levels throughout the modern lifespan (Supplementary Fig. 3). DHEA is not suited for this purpose and may even be dangerous, as in humans it will trigger the kill switch in unintended cells and tissues.

The origin of primates is the origin of DHEAS secretion by the adrenal

The adrenal gland and the gonads derive from the same embryonic anlage, the adrenogonadal primordium (Keegan & Hammer 2002, Vinson 2016), and the distinguishing feature of primates – their extraordinary levels of circulating DHEAS in their adult phase – derived from the novel differentiation of the adrenal gland into a contributor to androgen synthesis. This was a dramatic evolutionary event that may have been precipitated by the PAH exposure caused by the Chicxulub asteroid impact (Kaiho & Oshima 2017), resulting in the activation in proto primates of *Alu* elements that are stimulated by DNA damage (Rudin & Thompson 2001, Hagan *et al.* 2003). This novel contribution of the adrenal gland to androgen synthesis and secretion in the primate can be considered the most primitive form of adrenarche and the singular feature that initiated the primate lineage. It was also the first step in the evolution of the human-specific kill switch tumor suppression mechanism. We will pick up our discussion now with the second step in the evolution of the kill switch tumor suppression mechanism.

Step 2: *Alu*-mediated GLO deletion

For uncompetitive inhibition of G6PD to become irreversible, high intracellular levels of both inhibitor (DHEA) and substrate (G6P) are necessary. While high levels of DHEA can be obtained from the extraordinary amounts of DHEAS in the circulation of 25-year-old humans, how is it possible for G6P to accumulate in TP53-affected cells when multiple enzymatic pathways exist across diverse species that act as efficient sinks for G6P? For example, the ability to synthesize vitamin C (ascorbate) is a characteristic of almost all mammals, and because it utilizes G6P as its initial substrate and is induced by elevated ROS, it would oppose kill switch function by preventing the intracellular accumulation of G6P required for uncompetitive inhibition of G6PD to become irreversible. This obstacle to kill switch function was removed by deletion of gulonolactone oxidase (GLO), the final enzyme in the synthesis of ascorbate in the genomes of Haplorrhine primates (Fig. 1). By GLO deletion, Haplorrhine primates were rendered auxotrophic for vitamin C, but this unquenchable sink for G6P was eliminated (Nyce 2019). Without this crucial early step, subsequent development of the kill switch tumor suppressor mechanism would have been impossible and

Figure 1

The second major step in the evolution of the human-specific kill switch tumor suppression system was the *Alu*-mediated inactivation of GLO activity in Haplorrhine primates. The numbers above each species represent their levels of circulating DHEAS, relative to human, which is set at 1.0. DHEAS levels in tarsiers, an endangered species, remain unknown. Hom, Hominini, and hominins. Hominins include those species regarded as human, directly ancestral to humans, or closely related to humans.

humans would never have been able to harness fire as a tool. It is of interest to note that the inactivating deletion within GLO was caused by the insertion of primate-specific *Alu* transposable elements (Challem & Taylor 1998, Inai *et al.* 2003), which may themselves have been activated by PAH generated in the PETM (Rudin & Thompson 2001, Hagen *et al.* 2003, Ranjit *et al.* 2016).

Step 3: Anthropoid primate-specific modification of glucose-6-phosphatase

Glucose-6-phosphatase (G6PC) metabolizes G6P to glucose and inorganic phosphate, thereby representing another significant sink for G6P that would thwart kill switch function by preventing G6P accumulation in TP53-affected cells. G6PC activity is modulated by peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1alpha), which directs hepatic nuclear factor-4alpha (HNF4alpha), a member of the steroid/thyroid hormone receptor superfamily, to a specific dodecanucleotide activating regulatory site in the G6PC promoter. PGC1alpha is potently stimulated by DHEA (Yokokawa *et al.* 2015), explaining why DHEA is non-toxic to rodents – by stimulating G6PC activity, DHEA prevents accumulation of G6P in rodents, such that uncompetitive inhibition of G6PD by DHEA can never become irreversible. However, Schilling *et al.* (2008) have demonstrated that a different situation exists in humans. They identified a sequence motif in the G6PC promoter immediately downstream from the HNF4alpha-binding site that species specifically regulates PGC1alpha regulation of G6PC activity. In rodents, this sequence is ACAG, which Schilling and colleagues demonstrated, is permissive for PGC1alpha-mediated activation of G6PC activity. In humans, however, Schilling *et al.* (2008) demonstrated that this sequence motif has been changed to GAAT, which uncouples PGC1alpha from the activation of G6PD. In a species-specific manner, then, G6P can accumulate in humans in the presence of DHEA, which it cannot do in rodents. We extended this work and demonstrated that the GAAT sequence occurs throughout the anthropoid lineage, and that it is specific for this lineage (Supplementary Fig. 4). Thus, inactivation of GLO and this alteration in the sequence motif within the G6PC promoter were both required to enable G6P to accumulate to intracellular levels capable of driving uncompetitive inhibition of G6PD to irreversibility in TP53-affected cells (Fig. 2).

The canonical sequence motif at this G6PC promoter site in most vertebrate animals is GCAG (Supplementary

Figure 2

Alteration of G6PC promoter sequence motif enabled further evolution of the anthropoid primate-specific kill switch tumor suppressor system (Nyce 2018).

Fig. 4). Considering the exposure to PAH experienced by primates during the PETM, it is thus of interest that the C to A and G to T mutations that created the anthropoid primate-specific GAAT sequence motif in the G6PC promoter *are the signature mutations of PAH exposure* (Kucab *et al.* 2019). This suggests that environmental exposure to PAH helped shape the evolution of the kill switch mechanism, enabling anthropoid primates to exploit the PAH-contaminated environment that they inhabited.

Guidance by the *lex naturalis*

Using empirical dynamic modeling, we have identified a relationship between body size (S), lifespan (Li), species-specific mechanism of tumor suppression (T), and exposure to carcinogens (E) resulting from the exploitation of a specific niche, such that a change in any one of these variables requires an equilibrating change in one or more of the others in order to maintain lifetime cancer risk, R, at a value of about 4%, as observed in virtually all larger, longer-lived species under natural conditions (Abegglen *et al.* 2015). As long as equilibration is possible between these dependent variables, R will remain fixed at about 4%. Figure 3 shows the *lex naturalis* equation for a species stably integrated into its environment. It represents a snapshot in time, enabling the dependent variables of the equation (S, Li, T, and E) to be shown in a normalized configuration. The *lex naturalis* equation can equally

Figure 3

A normalized lex naturalis, representing a snapshot of a species with the dependent variables adult body size (S), lifespan (Li), species-specific mechanism of tumor suppression (T), and carcinogen exposure (E) in equilibrium to maintain lifetime cancer risk (R), at a value of about 4%.

validly be drawn to illustrate the equilibrating changes that occurred during a speciation event; for example, to illustrate the improvements in species-specific tumor suppression mechanism (T), that occurred to offset increases in body size (S), and so on.

Anthropoid primates dramatically increased in size following the combination of GLO deletion and G6PC promoter modification that improved 'kill switch' function

The earliest (56 MYA) primate fossils so far recovered are of a diminutive species known as *Archicebus achilles*, adult animals of which had a body length of perhaps two to three inches and a body weight estimated to be about 38g (Ni *et al.* 2013, Morse *et al.* 2019). That GLO deletion by itself was insufficient to enable significant increase in body size as a mechanism of speciation and is indicated by the fact that modern tarsiers, which were recipients of GLO deletion but not G6PC modification, remain small, averaging about 50–60 g in body mass. But within the anthropoid lineage, the basal catarrhine *Aegyptopithecus zeuxis* (30 MYA), with an estimated body mass of 6.7 kg (Simons *et al.* 2007), demonstrates that the combination of GLO and G6PC improvements to 'kill switch' function enabled a remarkable 150-fold increase in body mass from basal primates such as *Archicebus achilles*.

Nevertheless, the GLO and G6PC modifications cannot account for all increases in size in the anthropoid lineage because New World monkeys (Platyrrhines) also have the combination of GLO and G6PC 'kill switch' improvements and yet were exceeded in body size as a lineage quite dramatically by the Old World monkeys (Cercopithecoids). For example, the critically endangered northern Muriqui (*Brachyteles hypoxanthus*), that along with the southern Muriqui (*Brachyteles arachnoides*) represent the largest New World primates, reach a body mass of 15 kg (33 lbs), are dwarfed by the largest Old World monkey, the Mandrill (*Mandrillus sphinx*), which has an average body mass of 33 kg (73 lbs). Similarly,

the *Hominoidea* were enabled for much larger body size than were the Old World monkeys. According to the *lex naturalis*, these facts clearly predicted that there must be additional 'kill switch' improvements that distinguished cercopithecoid from platyrrhine primates and hominoids from cercopithecoids, but that we had not yet identified. We began a search to uncover them.

Step 4: Differentiation of the *zona reticularis* in catarrhine primates, producing an intermediate form of adrenarche

While non-primate animals derive virtually all of their DHEA from gonadal synthesis, primates have evolved a differentiation program that enables their adrenals to secrete DHEAS into the circulation. While the other tissues of the adrenal gland function throughout life – the *zona glomerulus* producing mineralocorticoids, and the *zona fasciculata* producing glucocorticoids – the *zona reticularis* emerges suddenly at about 6 years of age in humans, initiating adrenarche, the flooding of the bloodstream with prodigious amounts of DHEAS. Adrenarche occurs earlier in chimpanzees and bonobos, at 2–3 years of age (Behringer *et al.* 2012, Sabbi *et al.* 2019). Because gonadal tissue appears to regulate sexual dimorphism in humans, chimpanzees, and bonobos just as it does in other mammals, the evolutionary purpose of adrenarche has remained an enigma. DHEAS is also a neurosteroid, and its increases at adrenarche appear to parallel patterns of cortical maturation, prompting the suggestion that it plays an important role in extended brain maturation in humans (Campbell 2006). But the sudden flooding of the circulation with DHEAS, timed as it is in the developmental period immediately preceding the onset of adult body size, suggested to us that adrenarche plays an additional role as an enabling 'improvement' to kill switch function in humans, chimpanzees, and bonobos, focusing DHEAS secretion upon the developmental phase when it is needed (Fig. 4).

There is evidence to suggest that the origins of adrenarche exist much earlier than *Pan* and *Homo*, in the catarrhine lineage (Bernstein *et al.* 2012), where it may have also acted as an 'improvement' enabling increased body size, thereby distinguishing catarrhine from platyrrhine primates. Thus, a series of histologic and endocrine analyses demonstrate that catarrhine primates of both sexes have a fully functional *zona reticularis* and show an adrenarche-like secretion of DHEAS, albeit initiating much earlier than the onset

Figure 4

The catarrhine lineage came into existence as a result of the evolution of an intermediate form of adrenarcho as an 'improvement' in their kill switch tumor suppression mechanism, enabling increases in body size that remained unavailable to Platyrrhine primates, which did not evolve this 'improvement'.

of adult phase (Abbott & Bird 2009, Conley *et al.* 2011, 2018), while platyrrhine primates such as the common marmoset (*Callithrix jacchus*) do not (Pattison *et al.* 2009). The advent of an intermediate form of adrenarcho in catarrhines delivers DHEAS to the circulation closer to the developmental period when it will be needed, that is, at the conclusion of the small-bodied adolescent phase and just prior to the growth period that produces adult body size. By focusing DHEAS on adult body size, the evolution of adrenarcho in catarrhine primates enabled the Old World monkey lineage to explore substantial increases in body size as part of this lineage's speciation strategy. The lack of an equivalent mechanism in New World monkeys acted as a significant constraint upon increased body size as a speciation strategy.

What about the *hominoidea*?

The GLO deletion that had made Haplorrhine primates auxotrophic for vitamin C had also removed from the primate equation a major contributor to redox stability. Ascorbic acid is a potent antioxidant, and the loss of the ability to synthesize it *de novo* would have dramatically increased intracellular ROS concentrations (Challem & Taylor 1998). ROS are widely considered to contribute to the aging process, that is, to act as a negative pressure

limiting lifespan (Munro & Pamerter 2019, Munro *et al.* 2019). Since increases in body size are inefficient if they are not accompanied by simultaneous increases in lifespan, the *lex naturalis* had pointed us in the direction of finding a replacement antioxidant to substitute for the loss of the ability to synthesize vitamin C. With this clue in mind, we turned our attention to the search for an antioxidant that replaced ascorbate in the hominoids, enabling their increase in body size.

Step 5: Increased circulating uric acid as a critical element of kill switch evolution

One candidate molecule to replace the antioxidant activity of vitamin C is uric acid. Like vitamin C, uric acid is a potent antioxidant. In fact, with respect to one type of DNA-damaging agent (quinones) formed from the PAH produced in fire-combusted organic materials, uric acid is *superior* to vitamin C in their detoxification (Terao & Matsushita 1988). Based on *in vitro* experiments showing that uric acid was a powerful scavenger of a wide variety of ROS, in the 1980s Bruce Ames and colleagues made the suggestion that the high circulating levels of uric acid were responsible for the increases in lifespan observed in humans (also observed in other hominoids) as compared to more primitive primate species (Ames *et al.* 1981). In more recent times, a positive correlation between serum uric acid levels and lifespan in mammals has been reported (Cutler *et al.* 2019).

In our effort to investigate uric acid as a replacement for the antioxidant activity of vitamin C in post-Haplorrhine primates, we had to retrace our steps to basal Catarrhines. Thus, in addition to differentiation of the *zona reticularis* in basal catarrhine primates, there also occurred at this stage of primate evolution the first of what would become a series of changes in uric acid metabolism apparently contributing as improvements to T in the primate *lex naturalis*. Thus, Tan and colleagues investigated the kinetics and evolution of the URAT1 transport protein that is responsible for determining the amount of uric acid that is salvaged by the kidney and returned to the circulation (Tan *et al.* 2016). They determined that URAT1 of Catarrhine primates diverged sharply from the high affinity, high capacity kinetics of basal anthropoid primates (which carried into the Platyrrhines) and the low affinity, high capacity kinetics of URAT1 in the Strepsirrhines. Rather, beginning with the Catarrhines, a high affinity and *low capacity* version of URAT1 evolved that was ideal for maintaining high,

constant levels of circulating uric acid. These authors noted that this evolutionary pattern suggested positive selection for increasing levels of circulating uric acid during primate evolution, but at the time could offer no suggestion on what the function of uric acid might be. Our analysis indicates that URAT1 fine tuning was the first in a series of evolutionary steps that would make uric acid, and additional mechanisms for its transport into individual cells, a critical component of the human kill switch tumor suppression mechanism.

In this regard, it turns out that hominoids are *double* knockouts. Not only was vitamin C synthesis knocked out by GLO deletion early on in primates, initiating the Haplorrhine lineage, but the enzyme responsible for the elimination of uric acid – uric acid oxidase (UOX) – was also knocked out, by a series of much later mutations (≈ 20 MYA) occurring during the Miocene epoch, creating the *hominidae* and lesser ape lineages. Inactivation of UOX – and the consequent increase in circulating uric acid that it causes – appears to have been so crucial for hominoid evolution that independent inactivation events at completely different sites in the UOX gene occurred in the hominid and gibbon lineages (Wu *et al.* 1992, Oda *et al.* 2002). The mutation that participated in the evolution of the *hominidae* occurred in codon 33 of UOX, while that which participated in the evolution of the *hylobatidae* occurred in codon 18. Still further inactivating mutations in UOX occurred in the last common ancestor of *Pan* and *Homo* species, in intron 2, and codon 187 (Kratzer *et al.* 2014).

UOX (also called uricase) is the enzyme responsible for the degradation of uric acid. Uric acid is just a steppingstone to further degradation of purines in most species, but is the endpoint in purine degradation in hominids, because of the loss of UOX gene activity in this lineage. Loss of UOX in hominids causes uric acid to reach levels as high as 400 μM in modern humans, causing a disease unique to the hominoid lineage, gout (Messerli & Bernier 2019). Inactivation of UOX – and the consequent increase in circulating uric acid that it causes – appears to be so crucial for anthropoid evolution that independent inactivation events at completely different sites in the UOX gene occurred in the hominid and gibbon lineages (Wu *et al.* 1992, Oda *et al.* 2002). Support for UOX inactivation as a component of the primate kill switch (by enabling the increase in longevity that makes increased body size efficient) comes from a recent study out of the National Institutes of Health's National Institute on Aging. In this work, UOX^{+/-} knockout mice were observed to have large increases in circulating uric acid and an increase in longevity (Cutler *et al.* 2019).

But the transformation of URAT1 kinetics and the inactivation of UOX, together creating high circulating levels of uric acid, was not a complete solution to the ROS problem created by GLO deletion. It is not enough to have high levels of this potent antioxidant circulating in the bloodstream. It must be brought into the cell, where toxic ROS are generated. And for the kill switch to operate, such a transport of uric acid must be withheld from p53-affected cells.

Step 6: Uric acid transport into the cell put under p53 control

Only hominoid primates have high uric acid blood levels. Add to this the fact that more than 90% of uric acid is reabsorbed by the kidneys instead of being excreted, and it becomes clear that uric acid has been converted from a waste product (as it is in most other species) to something useful in hominoid primates. As noted, the usefulness of uric acid may be that it enabled this lineage to overcome the increase in ROS caused by loss of the ability to synthesize vitamin C. But uric acid in the circulation cannot neutralize ROS inside a cell. For this, active transport mediated by a cell-surface protein is required, in the same way that it is for DHEAS in the circulation.

Uric acid is imported into the cell by a widely expressed cell-surface protein called SLC2A9 (<https://www.proteinatlas.org/ENSG00000109667-SLC2A9/tissue>). Itahana *et al.* (2015) have made the important discovery that SLC2A9 is under p53 control in hominids. These authors demonstrated that in human cells undergoing oxidative stress, SLC2A9 expression increased in a p53-dependent manner – if they knocked out p53 expression, SLC2A9 expression was eliminated as well, and uric acid was not transported from the circulation to the interior of the cell. They showed that active expression of SLC2A9 in TP53-competent cells reduced ROS and protected against DNA damage and cell death. Putting SLC2A9 under positive TP53 control represents an additional critical event in the evolution of the human-specific kill switch tumor suppression mechanism. Thus, all normally functioning cells with active TP53 are protected from intracellular ROS by the import of antioxidant uric acid, as needed. In effect, uric acid replaced vitamin C as an antioxidant, but in a manner that was, unlike vitamin C, completely dependent upon there being active TP53 in the cell. This critical next step in hominid evolution also potentiated the selective killing power of the primate-specific kill switch tumor suppression mechanism,

such that TP53 inactivation not only triggered the active import of circulating DHEAS into the cell, but now switched *off* the import of antioxidant uric acid as well. In the p53-affected hominid cell then, DHEAS is imported and de-sulfated to DHEA, enabling irreversible inhibition of G6PD, thereby elevating ROS to levels that are catastrophic for the cell. Simultaneously, the import of uric acid that might oppose cell death by neutralizing ROS is switched *off* by p53 inactivation (Fig. 5).

Step 7: Further improvements in T required by meat consumption

The last common ancestor of chimpanzees and hominins distinguished itself from the gorilla and the orangutan by including red (mammalian) meat in its regular diet. The International Agency for Research on Cancer (IARC) has classified red meat as 'probably carcinogenic,' and heat-processed meat as 'carcinogenic' (https://www.iarc.fr/wp-content/uploads/2018/07/pr240_E.pdf). Follow-on studies have provided additional evidence demonstrating the carcinogenicity of red meat in a variety of human cancers (Dialo *et al.* 2018). In a recent large study out of the National Cancer Institute which followed almost a half million people with a median follow-up of 15.5 years, substitution of plant protein for red meat protein was found to substantially reduce cancer risk (Liao *et al.* 2019). The addition of red meat in the diet of the last

common ancestor of chimpanzees and hominins thus increased carcinogen exposure, E, which was countered by an offsetting increase (almost three-fold) in circulating DHEAS, and by precisely focusing adrenarche to precede the onset of adult body size (Fig. 6). Mechanisms by which circulating DHEAS were increased during the evolution of the *homininae* are likely to have involved transcription factor-binding site changes (Bernstein *et al.* 2012). The mechanisms by which adrenarche focuses DHEAS secretion in a development-specific manner is under intensive investigation (Thomas *et al.* 2015, Udhane & Fluck 2016, Maizoub & Topor 2018).

The *lex naturalis* explains important features of primate evolution

The *lex naturalis* teaches that increases in body size and lifespan cannot occur in vertebrate animals without corresponding improvements in species-specific mechanism of tumor suppression (T). Increases in carcinogen exposure also require improvements in T for the species to remain stable, that is, with R maintained within limits required by the *lex naturalis*. Thus, chimpanzees and early hominins (e.g. *Australopithecus afarensis*) could not significantly increase size or lifespan, even though they had improved their species-specific mechanism of tumor suppression by augmenting their circulating DHEAS, because they evolved from an ancestor that had substantially increased E by consuming red meat (Fig. 7A).

Figure 5

Increasing the levels of circulating uric acid, and putting the uric acid transporter under p53 control, dramatically improved kill switch function, enabling the remarkable increases in size of the *Hominoidea*. The existence of these components of the kill switch tumor suppression system was predicted by the *lex naturalis*. Adrenarche 2 refers to the intermediate form of adrenarche observed in catarrhine primates.

Figure 6

The last common ancestor of the chimpanzee and hominin lineages consumed meat, increasing E, and thereby requiring an equilibrating alteration in T, which consisted of a three-fold increase in circulating levels of DHEAS and the evolution of a complete form of adrenarche.

Gorillas and orangutans, on the other hand, preserved a very low E by maintaining a vegetarian diet. Accordingly, they were able to increase both body size and lifespan. Whereas gorillas emphasized body size in their solution of the *lex naturalis* (Fig. 7B), orangutans emphasized lifespan (Fig. 7C). Gorillas also doubled their levels of circulating DHEAS (compared to ancestral *Hominidae*) to enable their dramatic increase in body size. In fact, increasing body

size to expand niche exploitation reached remarkable levels overall in the primate lineage. The relative increase in size from primitive Haplorrhines, which weighed just a few tens of grams (Morse *et al.* 2019), to the gorilla, which can weigh 200 kg, exceeded even the increase in size from *Pakicetus* (the wolf-sized land animal that would give rise to whales) to *Balaenoptera musculus*, the blue whale, the largest creature ever to have lived on this planet. Clearly, the dependent variables of the *lex naturalis* required continuous equilibration during such expansion of the primate lineage, with S, body size, particularly competing with E, exploitation of a carcinogenic niche, to acquire the benefit of each improvement in T, species-specific mechanism of tumor suppression.

Figure 7

Lex naturalis equations for some hominid species. (A) *Lex naturalis* equation for the last common ancestor of chimpanzees and hominins, distinguished from other hominids by the consumption of meat, increasing E, necessitating an equilibrating increase in T. (B) *Lex naturalis* equation for gorillas, which maintained very low E by consumption of a vegetarian diet, enabling dramatic increase in body size, S. (C) *Lex naturalis* equation for orangutans, also vegetarian. In contrast to gorillas, orangutans emphasized lifespan over body size. (D) *Lex naturalis* equation for primitive *Homo sapiens*, who experienced dramatic increase in E as a result of the harnessing of fire and consumption of heat-processed meat. Although constrained, body size continually increased from *Homo habilis* to *Homo erectus* to *Homo sapiens* as human skills with fire, tools, and weapons increased consumption of meat, especially heat-processed meat, continuously increasing E during human evolution, requiring continuous improvements in T. Such improvements in T appear to have been accomplished by increasing circulating DHEAS.

Step 8: The pyrophilic primate: Selection for high levels of circulating DHEAS

The earliest archeological evidence for use of fire by our immediate ancestor, *Homo erectus*, occurs at sites in East Africa, including Cheswanja, near Lake Baringo, Koobi Fora, and Olorgesailie in Kenya, all dated to about 1.5 MYA (Gowlett 2016). Some authors attribute even earlier *Homo* species as adapting to fire prone environments 2 to 3 million years ago in tropical Africa, in fact becoming dependent upon natural fire to survive the extreme and rapid fluctuations between closed canopy forests, woodland, and grasslands that occurred at this time (Parker *et al.* 2016). As we have noted, humans are the only primate to have harnessed fire as a tool, although other primates such as the chimpanzee (and even non-primates, such as the hawk) capitalize upon natural fires as excellent sites at which to forage (Pruetz & Herzog 2017). The harnessing of fire led to PAH exposure levels in unventilated human habitats that are far in excess to anything that we can imagine in the modern world. PAH are potent mutagens, carcinogens, and teratogens and therefore critically increase E, at the expense of other of the dependent variables of the *lex naturalis*, particularly S and Li. Although a steady increase in body size did occur from the Australopithecines to and through *Homo* species, the intense increase in E experienced by the *Homo* lineage as a result of the harnessing of fire set significant constraints upon such increases. Despite such constraints, steady increases in body size occurred as *Homo* species evolved, clearly adaptive in an environment dominated as it was by large carnivores and intertribal warfare. But to achieve these increases in body size, humans required still further adaptive improvements to T, and they acquired those improvements by undergoing selection for members of the

species who had the highest levels of circulating DHEAS and by continuing to accept constraints upon lifespan, as compared to gorillas and especially to orangutans (Fig. 7D).

Intelligence in primates also gives the appearance of being related to circulating levels of DHEAS, although the totality of factors involved in this aspect of primate evolution are clearly manifold. DHEAS has been shown to play a critical role in human cognition and memory (Nguyen *et al.* 2018) and may have been doing so throughout primate evolution. With increasing intelligence in human species, the ability to fashion tools and weapons for hunting and butchering increased meat consumption still further, which many believe may have fueled encephalization (Richards 2002, Pontzer *et al.* 2016). Evidence for the use of stone tools to cut and strip meat from bones occurred by at least 2.6 MYA, as demonstrated by archeological sites that link stone tools with cut-marked bones (Wrangham *et al.* 1999, Plummer 2004, Pobiner *et al.* 2008, Merritt 2017). Eating energy-dense meat and the harnessing of fire together dramatically increased E in *Homo* species, which was offset by increased levels of circulating DHEAS, and constraint upon increase in size, and even more constraint upon lifespan, while brain size and function increased without similar constraint.

Improvements in kill switch tumor suppression occur at every major branch point in primate evolution that is followed by increased body size and lifespan

Our central discovery is that malignant transformation represents a limiting force opposing vertebrate speciation, and that species-specific mechanisms of tumor suppression evolved as a counterforce to overcome such opposition. Species-specific mechanisms of tumor suppression are thus fundamental elements of vertebrate speciation without which adaptive increases in body size and lifespan could not occur. *Improvements in the primate-specific kill switch tumor suppression mechanism occur at every branch point in the tree of primate evolution in which adaptive increases in body size and lifespan, or increased exposure to a carcinogenic environment, subsequently arise (Fig. 8).*

The dis-equilibrated *lex naturalis* equation of modern humans

The *lex naturalis* explains the current increase in R that has occurred in modern humans. As illustrated in Fig. 9, R in modern humans is 40%, tenfold higher than the 4%

of other large, long-lived animals, as well as primitive members of our own species. This tenfold increase in R has been driven by a twofold increase in adult body size, S, in modern humans as compared to primitive members of our species, made possible by the modern economy; and a more than threefold increase in lifespan, Li, made possible by modern medicine and public health measures. T, the human-specific mechanism of tumor suppression, has been rendered ineffectual in modern humans by the precipitous decline in circulating DHEAS that occurs after the primitive lifespan has been surpassed (Supplementary Fig. 2). Except for cigarette smokers and occupational exposure to carcinogens, E in modern humans may be equivalent to or possibly even reduced compared to what it was in PAH-saturated primitive humans surviving in their smoke-filled habitats. In terms of the *lex naturalis*, changes in the dependent variables of S, Li, and T have been so extreme that no equilibration between them has been possible, resulting in a dramatic increase in R, the effects of which our species is now experiencing.

The *lex naturalis*' prescription for 'normalizing' human cancer risk

The past five decades of cancer research have focused on finding a 'cure' for cancer or at least producing treatments that increase survival time. Great strides were made over these decades, but survival in cancer patients appears now to have reached an asymptotic boundary beyond which any further significant improvement may be impossible (Supplementary Fig. 5). Certainly a 'cure' now appears impossible due to the vast heterogeneity displayed by tumor cell populations. A different approach suggested by the *lex naturalis* is the 'normalization' of lifetime cancer risk in our species from its current aberrant 40% to the 4% that characterizes other vertebrates in the wild, including our own in the primitive setting in which it evolved (Fig. 10).

T, species-specific mechanism of tumor suppression

Unlike the species-specific mechanisms of tumor suppression observed in other species, which are genetic (Abegglen *et al.* 2015, Sulak *et al.* 2016, Vazquez *et al.* 2018), the human-specific tumor suppression mechanism operates via a small molecule, DHEAS, and is therefore pharmacologically tractable. Thus, we can pharmacologically reconstitute peak levels of circulating

Figure 8

Improvements in the primate-specific kill switch tumor suppression mechanism occur at every branch point in the tree of primate evolution in which adaptive increases in body size and lifespan, or increased exposure to a carcinogenic environment, subsequently arise. Increases in size during primate speciation reached an astonishing level, surpassing even those from *Pakicetus*, the wolf-sized land mammal that gave rise to the whales, to *Balaenoptera musculus*, the Blue whale. Int. adrenarche, intermediate adrenarche.

DHEAS as soon as they begin to decline and maintain these peak levels throughout the modern lifespan. By this measure, the *lex naturalis* predicts that we may be able to restore a lifetime cancer risk approaching 4% in modern humans despite even further increases in lifespan.

E, carcinogen exposure

We know from occupational exposures, and from the lung cancer epidemic that followed the introduction of tobacco products after the First World War, and its decline

after the Surgeon General forced tobacco companies to put warnings on cigarette packaging, that hotspots of carcinogen exposure exist and drive E to exceedingly high levels in exposed individuals. We should therefore continue, with increased vigor, to eliminate all human exposure to carcinogens, in order to reduce E to as low a figure as possible – including the carcinogenic potential of red meat. The *lex naturalis* suggests the possibility that the carcinogenicity of red meat may derive not from carcinogens that it contains, but rather from its ability to influence adult body size when consumed during developmental growth periods that occur prior to puberty.

Figure 9

Lex naturalis equation for modern humans. Due to the modern economy, body size, S, has more than doubled compared to primitive members of our species. Due to modern medicine and public healthcare systems, Lifespan, Li, has more than tripled. This has left aging humans without a functioning species-specific mechanism of tumor suppression, T, because circulating DHEAS precipitously declines after the age of 25, in keeping with the 25–30 year lifespans of primitive humans. Consequently, due to the impossibility of equilibration among the dependent variables, R has dramatically increased.

Figure 10

The *lex naturalis* prescription to 'normalize' lifetime cancer risk, R, in our species.

S, adult body size

As demonstrated in Supplementary Fig. 6, men have a significantly higher lifetime cancer risk than women do. The average man is also significantly taller than the average woman, a fact which the *lex naturalis* suggests may be responsible for some, perhaps most of the increased lifetime cancer risk for men. There is additional evidence implicating increasing height with increasing lifetime cancer risk in our species. For example, the recent 'million women study,' which followed 1,297,124 women for a median time of 9.4 years each, reported an overall 16% increase in cancer risk for every 10 cm (4 inches) in height above average (Green *et al.* 2011). This association of increased cancer risk with increased height has been confirmed by additional studies performed in 144,701 women (median follow-up, 12 years) (Kabat *et al.* 2013), and in 310,000 male and female UK Biobank participants (Ong *et al.* 2018). Thus, the taller a human is, the greater their lifetime cancer risk, in both sexes. Conversely, the shorter a human is, the lower their lifetime cancer risk, in both sexes. At this shorter end of the height spectrum, studies of dwarf humans with Laron Syndrome – one of which studies lasted 57 years – demonstrated a near total absence of cancer in these long-lived, small-bodied humans (Janecka *et al.* 2016, Laron & Kauli 2016).

According to the *lex naturalis*, a short child is a well-adapted child

Correlations between nutritional status – associated with socioeconomic status – and adult height have led to a nutrition philosophy in which developmental success is measured as a function of increased stature (Perkins *et al.* 2016, Park *et al.* 2019). As evidence of this, consider the physical exams that we subject our children to during their development. All of the height indices by which developmental 'progress' is measured by pediatricians are designed to show where our children stand with respect to the mean, and a pediatrician is apt to express concern if a child is substantially below that mean ('height-for-age' Z score) and to do the opposite if the child is well above. This sets up a positive feedback system which drives toward greater and greater height in our species. Increased stature was immensely important in the primitive human landscape, dominated as it was by predation by large carnivores, and by intertribal warfare, and in which humans lived short, accelerated lives. But outside of sporting arenas, increased stature is not useful in the modern world and is working against us as a species.

Our continued, misplaced preoccupation with increasing stature is one of the principal dis-equilibriums in the *lex naturalis* of modern humans. How might we begin to correct this disequilibrium? Two growth periods have been found to be important in determining adult height. The first of these occurs from conception to about 2 years of age. The second occurs from 2 years up to the onset of adrenarche. Overnutrition that stimulates Z during these growth phases may be just as bad for our children, in the long run, as malnutrition. If we can find ways to reduce adult height (without negatively affecting mentation) by adjusting our nutritional goals for our children during these critical growth periods, re-equilibration of adult body size, S, combined with DHEAS reconstitution of the 'kill switch,' may enable rapid normalization of lifetime cancer risk, despite even further increases in lifespan, Li.

Li, Lifespan

Lifespan is not a dependent variable that humans are likely to adjust in a downward direction in order to equilibrate R, lifetime cancer risk – although certainly reducing Li to that of primitive humans would do so. It remains to be determined what the possible human lifespan is, but with proper equilibration of the *lex naturalis*, it would not be surprising to see it rise significantly above its current value. Of course, such long life would only be desirable if we could live it in relative health, absent of many of the diseases of old age which now plague us. The growing literature on the effects of DHEAS in cognition, memory, and other aspects of brain function suggest the possibility that reconstitution of T and reduction in S may have positive effects beyond the normalization of R.

A new strategy: 'Normalization' of lifetime cancer risk

The *lex naturalis* predicts that we can 'normalize' human lifetime cancer risk by pharmacologically reconstituting our kill switch tumor suppression system. It would be useful to achieve some verification of the 'normalization' hypothesis in an animal model, but this is ruled out by the *lex naturalis*: *the existence of species-specific mechanisms of tumor suppression prevent one vertebrate species from acting as a valid model system for cancer in another vertebrate species* (Supplementary Fig. 7). No other species evolved in the presence of such high levels of circulating DHEAS, rendering meaningless preclinical toxicology and efficacy studies performed in non-human species.

The practical question that we are thus faced with is that the potential to normalize human lifetime cancer risk from its current 40% to the 4% observed in other large, long-lived animals is a testable hypothesis, but only in humans. As we have noted, the *lex naturalis* powerfully explains an array of longstanding questions in human biology. *Why the extraordinary levels of circulating DHEAS in humans, when DHEAS's proximate metabolite, DHEA, is an uncompetitive, potentially irreversible inhibitor of so crucial an enzyme as G6PD? Why the evolution of adrenarche, a developmental phase that floods the human circulation with DHEAS immediately preceding the onset of adult body size? Why the loss of GLO activity, leading to vitamin C auxotrophy, and the potential to develop scurvy? Why the evolution of a completely anthropoid primate-specific GAAT sequence motif in the G6PC promoter that enables inhibition of G6PD to become irreversible in the presence of DHEA? And why UOX deletion, leading to accumulation of circulating uric acid, and the disease of gout?* It is extremely unlikely that so many longstanding, unresolved questions in primate evolution all intersect at kill switch function, and obtain compelling explanation by such intersection, if that is not where they derive their evolutionary significance. We therefore argue that the kill switch we describe represents our species' primary defense against cancer, with a probability approaching 1, despite the impossibility of pre-confirmation in animal models. Similarly, the *lex naturalis* has powerful explanatory power not only for primate mechanisms of tumor suppression, but across the spectrum of vertebrates speciation (Supplementary Figs 7, 8, 9, 10, 11, and 12).

The IARC projects that by 2040 the number of new cancer cases will reach almost 30 million per year and cancer deaths nearly 17 million per year, and has warned that these are not numbers that we have any chance of treating our way out of (IARC 2018, 2019). The possibility of normalizing lifetime cancer risk in our species by addressing the disequilibrium in the modern *lex naturalis* offers an alternative, prevention strategy that has the potential to substantially mitigate the accelerating impact of cancer upon our species. Since DHEAS is a natural constituent of the human body, and is not a potent uncompetitive inhibitor of G6PD in the manner of DHEA, it is hard to imagine a safer clinical trial than the reconstitution of DHEAS to their peak levels and the maintenance of such levels throughout the modern lifespan. While it might be argued that maintenance of DHEAS at such high levels could aggravate hormone-sensitive tumors, such as breast and prostate cancers, the point of the kill switch tumor suppression mechanism is that it would prevent such tumors from developing in the first place. Considering the apparent

safety of DHEAS, and the dystopian cancer numbers that we are approaching guided by our current cancer research paradigms, clinical studies to test the normalization hypothesis should become a focus of discussion at the National Cancer Institute and the IARC – the only two agencies capable of conducting clinical investigations on the scale that will be required. Direct testing in humans will require breaking with a paradigm that formed in the absence of knowledge of the *lex naturalis* – that anti-cancer strategies must be pre-confirmed in animal models. But in view of the *lex naturalis*, abandonment of this paradigm appears to be the only prudent way forward.

Supplementary materials

This is linked to the online version of the paper at <https://doi.org/10.1530/ERC-19-0382>.

Declaration of interest

J W N has pending patents related to kill switch maintenance, patents he is willing to transfer to the NCI and/or IARC under certain conditions.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Acknowledgements

This work was made possible in part by the Food and Drug Administration, program identifiers: G003126-C-2195-SR1891; G003126-C-2195-SR1892; G003126-C-2195-SR1893; G003126-C-2195-SR1894; G003126-C-2195-SR1895. This manuscript is dedicated to the memory of the author's mentors, Sydney Weinhouse, Peter Magee, and George Hitchings. They were stellar scientists and exemplary human beings.

References

- Abbott DH & Bird IM 2009 Nonhuman primates as models for human androgen production: function and dysfunction. *Reviews in Endocrine and Metabolic Disorders* **10** 33–42. (<https://doi.org/10.1007/s11154-008-9099-8>)
- Abegglen LM, Caulin AE, Chan A, Lee K, Robinson R, Campbell MS, Kiso WK, Schmitt DL, Waddell PJ, Bhaskara S, *et al.* 2015 Potential mechanisms for cancer resistance in elephants and comparative cellular response to DNA damage in humans. *JAMA* **314** 1850–1860. (<https://doi.org/10.1001/jama.2015.13134>)
- Ames BN, Cathcart R, Schwiers E & Hochstein P 1981 Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. *PNAS* **78** 6858–6862. (<https://doi.org/10.1073/pnas.78.11.6858>)
- Behringer V, Hohmann G, Stevens JM, Weltring A & Deschner T 2012 Adrenarche in bonobos (*Pan paniscus*): evidence from ontogenic changes in urinary dehydroepiandrosterone sulfate levels. *Journal of Endocrinology* **214** 55–65. (<https://doi.org/10.1530/JOE-12-0103>)

- Bernstein RM, Sterner KN & Wildman DE 2012 Adrenal androgen production in cararrhine primates and the evolution of adrenarche. *American Journal of Physical Anthropology* **147** 389–400. (<https://doi.org/10.1002/ajpa.22001>)
- Campbell B 2006 Adrenarche and the evolution of human life history. *American Journal of Human Biology* **18** 569–589. (<https://doi.org/10.1002/ajhb.20528>)
- Challem JJ & Taylor EW 1998 Retroviruses, ascorbate, and mutations in the evolution of Homo sapiens. *Free Radical Biology and Medicine* **25** 130–132. ([https://doi.org/10.1016/s0891-5849\(98\)00034-3](https://doi.org/10.1016/s0891-5849(98)00034-3))
- Conley AJ, Plant TM, Abbott DH, Moeller BC & Stanley SD 2011 Adrenal androgen concentrations increase during infancy in male rhesus macaques (Macaca mulatta). *American Journal of Physiology: Endocrinology and Metabolism* **301** E1229–E1235. (<https://doi.org/10.1152/ajpendo.00200.2011>)
- Conley AJ, Moeller BC, Nguyen AD, Stanley SD, Plant TM & Abbott DH 2018 Defining adrenarche in the rhesus Macaque (Macaca mulatta), non-human primate models for androgen secretion. *Molecular and Cellular Endocrinology* **336** 110–116. (<https://doi.org/10.1016/j.mce.2010.12.022>)
- Cornish-Bowden A 1986 Why is uncompetitive inhibition so rare? A possible explanation, with implications for the design of drugs and pesticides. *FEBS Letters* **203** 3–6. ([https://doi.org/10.1016/0014-5793\(86\)81424-7](https://doi.org/10.1016/0014-5793(86)81424-7))
- Cutler RG, Camandola S, Feldman NH, Yoon JS, Haran JB, Arguelles S & Mattson MP 2019 Uric acid enhances longevity and endurance and protects the brain against ischemia. *Neurobiology of Aging* **75** 159–168. (<https://doi.org/10.1016/j.neurobiolaging.2018.10.031>)
- Diallo A, Deschasaux M, Latino-Martel P, Hercberg S, Galan P, Fassier P, Alles B, Gueraud F, Pierre FH & Touvier M 2018 Red and processed meat intake and cancer risk: results from the prospective NutriNet-Sante cohort study. *International Journal of Cancer* **142** 230–237. (<https://doi.org/10.1002/ijc.31046>)
- Fung MK, Schaller MF, Hoff CM, Katz ME & Wright JD 2018 Widespread and intense wildfires at the Paleocene-Eocene boundary. *Geochemical Perspectives Letters* **10** 1–6. (<https://doi.org/10.7185/geochemlet.1906>)
- Gebo DL, Daosto M, Ni X & Beard KC 2017 Phalangeal morphology of Shanhuang fossil primates. *Journal of Human Evolution* **113** 38–82. (<https://doi.org/10.1016/j.jhevol.2017.08.001>)
- Gowlett JAJ 2016 The discovery of fire by humans: a long and convoluted process. *Philosophical Transactions of the Royal Society of London Series B* **371** 20150164.
- Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V & Million Women Study collaborators 2011 Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. *Lancet: Oncology* **12** 785–794. ([https://doi.org/10.1016/S1470-2045\(11\)70154-1](https://doi.org/10.1016/S1470-2045(11)70154-1))
- Hagan CR, Sheffield RF & Rudin CM 2003 Human Alu element retrotransposition induced by genotoxic stress. *Nature Genetics* **35** 219–220. (<https://doi.org/10.1038/ng1259>)
- IARC 2018 Estimated number of incident cases from 2018 to 2040, all cancers, both sexes, all ages. (available at: http://gco.iarc.fr/tomorrow/graphic-isotype?type=0&population=900&mode=population&sex=0&cancer=39&age_group=value&apc_male=0&apc_female=0)
- IARC 2019 World cancer report: research for cancer. Prevention. (available at: https://www.iarc.fr/cards_page/world-cancer-report/)
- Inai Y, Ohta Y & Nishikimi M 2003 The whole structure of the human nonfunctional L-gulonolactone-gamma-lactone oxidase gene – the gene responsible for scurvy – and the evolution of repetitive sequences thereon. *Journal of Nutritional Science and Vitaminology* **49** 315–319.)
- Itahana Y, Han R, Barbier S, Lei Z, Rozen S & Itajana K 2015 The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense. *Oncogene* **34** 1799–1810. (<https://doi.org/10.1038/ncr.2014.119>)
- Janecka A, Kolodziej-Rzepa M & Biesaga B 2016 Clinical and molecular features of Laron syndrome, a genetic disorder protecting from cancer. *In Vivo* **30** 375–381.
- Kabat GC, Anderson ML, Heo M, Hosgood HD, Kamensky V, Bea JW, Hou L, Lane DS, Wactawski-Wende J, Manson JE, et al. 2013 Adult stature and risk of cancer at different anatomic sites in a cohort of postmenopausal women. *Cancer Epidemiology, Biomarkers and Prevention* **22** 1353–1363. (<https://doi.org/10.1158/1055-9965.EPI-13-0305>)
- Kaiho K & Oshima N 2017 Site of asteroid impact changed the history of life on Earth: the low probability of mass extinction. *Scientific Reports* **7** 14855.
- Keegan CE & Hammer GD 2002 Recent insights into organogenesis of the adrenal cortex. *Trends in Endocrinology and Metabolism* **13** 200–208. ([https://doi.org/10.1016/S1043-2760\(02\)00602-1](https://doi.org/10.1016/S1043-2760(02)00602-1))
- Kratzer JT, Lanasa MA, Murphy MN, Cicerchi C, Graves CL, Tipton PA, Ortlund EA, Johnson RJ & Gaucher EA 2014 Evolutionary history and metabolic insights of ancient mammalian uricases. *PNAS* **111** 3763–3768. (<https://doi.org/10.1073/pnas.1320393111>)
- Kucab JE, Zou X, Morganella S, Joel M, Nanda AS, Nagy E, Gomez C, Degasperis A, Harris R, Jackson SP, et al. 2019 A compendium of mutational signatures of environmental agents. *Cell* **177** 821.e16–836.e16. (<https://doi.org/10.1016/j.cell.2019.03.001>)
- Laron Z & Kauli R 2016 Fifty-seven years of follow-up of the Israeli cohort of Laron syndrome patients – from discovery to treatment. *Growth Hormone and IGF Research* **28** 53–56. (<https://doi.org/10.1016/j.ghir.2015.08.004>)
- Liao LM, Loftfield E, Etemadi A, Graubard BI & Sinha R 2019 Substitution of dietary protein sources in relation to colorectal cancer risk in the NIH-AARP cohort study. *Cancer Causes and Control* **30** 1127–1135. (<https://doi.org/10.1007/s10552-019-01210-1>)
- Maizoub JA & Topor LS 2018 A new model for adrenarche: inhibition of 3 β -hydroxysteroid dehydrogenase type 2 by intra-adrenal cortisol. *Hormone Research in Paediatrics* **89** 311–319. (<https://doi.org/10.1159/000488777>)
- Merritt SR 2017 Investigating hominin carnivory in the Okote member of Koobi Fora, Kenya with an actualistic model of carcass consumption and traces of butchery on the elbow. *Journal of Human Evolution* **112** 105–133. (<https://doi.org/10.1016/j.jhevol.2017.08.004>)
- Messerli FH & Burnier M 2019 Cardiovascular disease and uric acid: Is the not-so-innocent bystander becoming a true culprit and does the US black box warning for febuxostat indicate that not all uric acid lowering is beneficial? *European Heart Journal* **40** 1787–1789. (<https://doi.org/10.1093/eurheartj/ehz199>)
- Morse PE, Chester SGB, Boyer DM, Smith T, Smith R, Gigase P & Bloch JI 2019 New fossils, systematics, and biogeography of the crown primate Teilhardina from the earliest Eocene of Asia, Europe and North America. *Journal of Human Evolution* **128** 103–131. (<https://doi.org/10.1016/j.jhevol.2018.08.005>)
- Munro D & Pamerter ME 2019 Comparative studies of mitochondrial reactive oxygen species in animal longevity: Technical pitfalls and possibilities. *Aging Cell* **18** e13009. (<https://doi.org/10.1111/accel.13009>)
- Munro D, Baldy C, Pamerter ME & Treberg JR 2019 The exceptional longevity of the naked mole rat may be explained by mitochondrial antioxidant defenses. *Aging Cell* **18** e12916. (<https://doi.org/10.1111/accel.12916>)
- Nguyen T-V, Wu M, Lew J, Albaugh MD, Kelly N, Botteron KN, James J, Hudziak JJ, Vladimir S, Fonov VS, et al. 2018 Dehydroepiandrosterone impacts working memory by shaping cortico-hippocampal structural covariance during development. *Psychoneuroendocrinology* **86** 110–121. (<https://doi.org/10.1016/j.psyneuen.2017.09.013>)
- Ni X, Gebo DL, Dagosto M, Meng J, Tafforeau P, Flynn JJ & Beard KC 2013 The oldest known primate skeleton and early haplorhine evolution. *Nature* **498** 60–64. (<https://doi.org/10.1038/nature12200>)
- Nyce JW 2018 Detection of a novel, primate-specific 'kill switch' tumor suppression mechanisms that may fundamentally control cancer risk

- in humans: an unexpected twist in the basic biology of TP53. *Endocrine-Related Cancer* **25** R497–R517. (<https://doi.org/10.1530/ERC-18-0241>)
- Nyce JW 2019 Species-specific mechanisms of tumor suppression are fundamental drivers of vertebrate speciation: critical implications for the 'war on cancer.' *Endocrine-Related Cancer* **26** C1–C5. (<https://doi.org/10.1530/ERC-18-0468>)
- Oda M, Satta Y, Takenaka O & Takahata N 2002 Loss of urate oxidase activity in hominoids and its evolutionary implications. *Molecular Biology and Evolution* **19** 640–653. (<https://doi.org/10.1093/oxfordjournals.molbev.a004123>)
- Ong JS, An J, Law MH, Whiteman DC, Neale RE, Gharahkhani P & MacGregor S 2018 Height and overall cancer risk and mortality: evidence from a Mendelian randomization study on 310,000 UK Biobank participants. *British Journal of Cancer* **118** 1262–1267. (<https://doi.org/10.1038/s41416-018-0063-4>)
- Park JJH, Fang ML, Harari O, Dron L, Siden EG, Majzoub R, Jeziorska V, Thorlund K, Mills EJ & Bhutta ZA 2019 Association of early interventions with birth outcomes and child linear growth in low-income and middle-income countries: bayesian network meta-analysis of randomized clinical trials. *JAMA Network Open* **2** e197871. (<https://doi.org/10.1001/jamanetworkopen.2019.7871>)
- Parker CH, Keefe ER, Herzog NM, O'Connell JF & Hawkes K 2016 The pyrophilic primate hypothesis. *Evolutionary Anthropology* **25** 54–63. (<https://doi.org/10.1002/evan.21475>)
- Pattison JC, Abbott DH, Saltzman W, Conley AJ & Bird IM 2009 Plasticity of the zona reticularis in the adult marmoset adrenal cortex: voyages of discovery in the New World. *Journal of Endocrinology* **203** 313–326. (<https://doi.org/10.1677/JOE-08-0554>)
- Perkins JM, Subramanian SV, Smith GD & Ozaltin E 2016 Adult height, nutrition, and population health. *Nutrition Reviews* **74** 149–165. (<https://doi.org/10.1093/nutrit/nuv105>)
- Plummer T 2004 Flaked stones and old bones: biological and cultural evolution at the dawn of technology. *American Journal of Physical Anthropology: Supplement* **39** 118–164
- Pobiner BL, Rogers MJ, Monahan CM & Harris JW 2008 New evidence for hominin carcass processing strategies at 1.5 Ma, Koobi Fora, Kenya. *Journal of Human Evolution* **55** 103–130. (<https://doi.org/10.1016/j.jhevol.2008.02.001>)
- Pontzer H, Brown MH, Raichlen DA, Dunsworth H, Hare B, Walker K, Luke A, Dugas LR, Durazo-Arvizu R, Scholler D, et al. 2016 Metabolic acceleration and the evolution of human brain size and life history. *Nature* **533** 390–392. (<https://doi.org/10.1038/nature17654>)
- Pruetz JD & Herzog NM 2017 Savanna Chimpanzees at Fongoli, Senegal, navigate a fire landscape. *Current Anthropology* **58** S337–S350. (<https://doi.org/10.1086/692112>)
- Ranjit S, Midde NM, Sinha N, Patters BJ, Rahman MA, Cory TJ, Rai PSS & Kumar S 2016 Effect of polyaryl hydrocarbons on cytotoxicity in monocytic cells: potential role of cytochromes P450 and oxidative stress pathways. *PLoS ONE* **11** e0163827. (<https://doi.org/10.1371/journal.pone.0163827>)
- Richards MP 2002 A brief review of the archeological evidence for Paleolithic and Neolithic subsistence. *European Journal of Clinical Nutrition* **56** 1270–1278; 16 p following 1262. (<https://doi.org/10.1038/sj.ejcn.1601646>)
- Robson BE, Collinson ME, Riegel W, Wilde V & Scott A 2014 A record of fire through the Early Eocene. *Rendiconti Online della Società Geologica Italiana* **31** 187–188. (<https://doi.org/10.3301/ROL.2014.113>)
- Rudin CM & Thompson CB 2001 Transcriptional activation of short interspersed elements by DNA-damaging agents. *Genes, Chromosomes and Cancer* **30** 64–71. ([https://doi.org/10.1002/1098-2264\(2000\)999:999::AID-GCC1066>3.0.CO;2-F](https://doi.org/10.1002/1098-2264(2000)999:999::AID-GCC1066>3.0.CO;2-F))
- Sabbi KH, Muller MN, Machanda ZP, Otali E, Fox SA, Wrangham RW & Emery-Thompson M 2019 Human-like adrenal development in wild chimpanzees: a longitudinal study of urinary dehydroepiandrosterone-sulfate and cortisol. *American Journal of Primatology* e23064. (<https://doi.org/10.1002/ajp.23064>)
- Schaller ME, Fung MK, Wright JD, Katz ME & Kent DV 2016 Impact ejecta at the Paleocene-Eocene boundary. *Science* **354** 225–229. (<https://doi.org/10.1126/science.aaf5466>)
- Schilling MM, Oeser JK, Chandy JK, Flemming BP, Allen SR & O'Brien RM 2008 Sequence variation between the mouse and human glucose-6-phosphatase catalytic subunit gene promoters results in differential activation by peroxisome proliferator activator receptor gamma coactivator-1 alpha. *Diabetologia* **51** 1505–1514. (<https://doi.org/10.1007/s00125-008-1050-8>)
- Simons EL, Seiffert ER, Ryan TM & Attia Y 2007 A remarkable female cranium of the Early Oligocene anthropoid Aegyptopithecus Zeuxis (Catarrhini, Propithecidae). *PNAS* **104** 8731–8736. (<https://doi.org/10.1073/pnas.0703129104>)
- Sulak M, Fong L, Mika K, Chigurupati S, Yon L, Mongan NP, Emes RD & Lynch VJ 2016 TP53 copy number expansion is associated with the evolution of increased body size and an enhanced DNA damage response in elephants. *eLife* **5** e11994. (<https://doi.org/10.7554/eLife.11994>)
- Tan PK, Farrar JE, Gaucher EA & Miner JN 2016 Coevolution of URAT1 and uricase during primate evolution: implications for serum urate homeostasis and gout. *Molecular Biology and Evolution* **33** 2193–2200. (<https://doi.org/10.1093/molbev/msw116>)
- Terao J & Matsushita S 1988 Quinone formation from benzo(a)pyrene by free radicals: effects of antioxidants. *Free Radical Biology and Medicine* **4** 205–208. ([https://doi.org/10.1016/0891-5849\(88\)90040-8](https://doi.org/10.1016/0891-5849(88)90040-8))
- Thomas JL, Rajapaksha M, Mack VL, DeMars GA, Maizoub JA & Bose HS 2015 Regulation of human 3β-hydroxysteroid dehydrogenase type 2 by adrenal corticosteroids and product-feedback by androstenedione in human adrenarache. *Journal of Pharmacology and Experimental Therapeutics* **352** 67–76. (<https://doi.org/10.1124/jpet.114.219550>)
- Udhane SS & Fluck CE 2016 Regulation of human (adrenal) androgen biosynthesis – new insights from novel throughput technology studies. *Biochemistry and Pharmacology* **102** 20–33. (<https://doi.org/10.1016/j.bcp.2015>)
- Vazquez JM, Sulak M, Chigurupati S & Lynch VJ 2018 A zombie LIF gene in elephants is upregulated by TP53 to induce apoptosis in response to DNA damage. *Cell Reports* **24** 1765–1776. (<https://doi.org/10.1016/j.celrep.2018.07.042>)
- Vinson GP 2016 Functional zonation of the adult mammalian adrenal cortex. *Frontiers in Neuroscience* **10** 238. (<https://doi.org/10.3389/fnins.2016.00238>)
- Wrangham RW, Jones JH, Laden G, Pilbeam D & Conklin-Brittain N 1999 The raw and the stolen: cooking and the ecology of human origins. *Current Anthropology* **40** 567–594. (<https://doi.org/10.1086/300083>)
- Wu XW, Muzny DM, Lee CC & Caskey CT 1992 Two independent mutational events in the loss of urate oxidase during hominoid evolution. *Journal of Molecular Evolution* **34** 78–84. (<https://doi.org/10.1007/bf00163854>)
- Yokokawa T, Sato K, Iwanaka N, Honda M, Higashida K, Lemitsu M & Hashimoto T 2015 Dehydroepiandrosterone activates AMP kinase and regulates GLUT4 and PGC-1α expression. *Biochemical and Biophysical Research Communications* **463** 42–47.

Received in final form 12 November 2019

Accepted 9 December 2019

Accepted Manuscript published online 9 December 2019